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Abstract 
A 7-year-old boy with Tourette’s disorder, atypical pervasive developmental disorder, borderline mental retardation, and
a history of self-injurious behavior was treated for 21 months with clonidine transdermal patches at doses ranging from
0.1 to 0.5 mg weekly. When withdrawn from clonidine over 4 weeks to assess the need for continued therapy, the patient
developed multiple self-destructive behaviors involving the theme of suffocation. The importance of careful clinical mon-
itoring of the behavior of patients undergoing withdrawal from prolonged treatment with high doses of clonidine is em-
phasized. (J Child Neurol 1990;5:308-310).
Tourette’s disorder, a syndrome usually be-ginning in childhood and characterized by
chronic motor and phonic tics, occasionally is associ-
ated with self-injurious behavior. 1,2 Clonidine has
been proposed as a treatment for Tourette’s disorder
and for self-injurious behavior occurring in the con-
text of Tourette’s disorder.3 Few data are available,
however, to indicate when clonidine treatment
might be discontinued or the possible consequences
of discontinuation of treatment.
Withdrawal from clonidine can cause rebound
hypertension and tachycardia in adult hypertensiveS4
and can aggravate motor restlessness and tics in chil-
dren undergoing therapy for Tourette’s disorder.5 
5
The following is apparently the first report linking
clonidine withdrawal to self-injurious behavior in
patients with Tourette’s disorder.
Case Report
A 71/2-year-old white boy was referred to the Behavior Dis-
orders Clinic of the Child and Adolescent Psychiatric Hos-
pital, University of Michigan Medical Center, for treatment
of Tourette’s disorder.
The patient was the 4350-g product of an induced de-
livery following 43 weeks gestation complicated by hypere-
mesis and a prolapsed umbilical cord. In his first year, the
infant suffered continual vomiting and had gained no
weight by 11 months of age. Fine motor skills and lan-
guage acquisition were delayed. Gross motor milestones
reportedly were normal. Language at age 4 years was char-
acterized by poor articulation, pronoun reversals, and
echolalia.
The patient was noted to be hyperactive in his second
year and by age 21/2 displayed severe hyperactivity, head-
banging, self-biting, hair-pulling, touching hot appliances,
and tantrums. He also exhibited mannerisms such as toe-
walking, hand-flapping, and rocking. Hypoxanthine gua-
nine phosphoribosyltransferase was in the low-normal
range. At age 5 years, the patient began to exhibit simple
motor tics including eye-blinking, mouth-opening, and
shoulder jerks, and complex tics such as light-switching
and touching other children. Phonic tics included grunts,
simple words, and profanity.
Family history was noteworthy for Tourette’s disorder
in two siblings, tic disorders in two maternal uncles, and
learning disabilities in 16 of 32 maternal second cousins.
Family history was negative for mental retardation, epi-
lepsy, psychiatric hospitalization, affective disorder, or sui-
cide.
At age 6 years, the patient was placed on clonidine
transdermal patches (Catapres TTS) at doses gradually in-
creasing over the next 21 months to a maximum of 0.5 mg
(20 ¡.tg/kg) weekly. This resulted in marked reduction in
motoric overactivity, according to parent and clinician re-
ports. Self-injurious behaviors disappeared during the pe-
riod of treatment, while tics showed a modest
improvement.
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The patient was referred to the author at age 7.5 be-
cause of increasingly severe tics and behavioral problems
unresponsive to clonidine.
On examination, the blood pressure was 100/70 mm
Hg and the pulse 72 beats/min. General physical and neu-
rologic examinations were normal except for mild hyperte-
lorism and multiple nonlocalizing neurologic soft signs
consistent with developmental delay. The patient estab-
lished rapport readily. Speech articulation was impaired.
Gross activity level and ability to persist in tasks were nor-
mal for developmental age. Mood was normal, and psy-
chotic manifestations were absent. Recent psychological
testing demonstrated borderline mental functioning.
The patient met Diagnostic and Statistical Manual of
Mental Disorders, 3rd ed revised criteria for Tourette’s dis-
order, pervasive developmental disorder not otherwise
specified, and borderline mental retardation.
The patient was placed on fluoxetine in doses up to 20
mg daily, with the effect of extinguishing severe tantrums
that had hitherto occurred several times daily.
At age 7 years 11 months, arm-throwing and bruxism
become functionally incapacitating, and tolerance to cloni-
dine was suspected. Medication was tapered by 0.1 mg
weekly. At doses of 0 to 0.2 mg weekly, ratings on the Ab-
breviated Teacher’s Questionnaire’ rose from a previous
baseline of 1.4 to 2.6 (of a possible maximum of 3.0). Mul-
tiple self-destructive behaviors occurred during the next 3
weeks. Following a disagreement with his mother, in a fit
of anger, the patient attempted to suffocate himself with a
pillow. On another occasion he placed a plastic bag over
his head and likely would have expired had his mother not
found him stumbling down the stairs frantically grasping
the bag. At school, he turned blue strangling himself with
an elastic lanyard. At home, he made a similar gesture
with a rubber band. Finally, he fell or jumped from the
roof of a garage, sustaining minor bruises and abrasions.
All but the first of these acts were spontaneous and unac-
companied by depressed or angry affect. Between epi-
sodes, his mood, appetite, and interest in friends and
activities were stable.
One week following discontinuation of clonidine, the
patient displayed a supine blood pressure of 142/84 mm
Hg, with a pulse of 100 beats/min. He was markedly over-
active. His mood was cheerful and his affect somewhat
brighter than observed on previous occasions. He denied
suicidal ideation.
The patient was placed on haloperidol, 1 mg twice
daily. Tics decreased by 23%, and his score on the Abbrevi-
ated Teacher Questionnaire fell to 1.8. In the fourth week
of haloperidol treatment, another episode of self-strangling
with a lanyard occurred. Haloperidol was discontinued,
and the clonidine patch was reinstated at a dose increasing
to 0.3 mg/week. The Abbreviated Teacher Questionnaire
score dropped to 0.7, and teacher-rated stereotypies
dropped by 55%. On examination, blood pressure was 95/
65 mm Hg, pulse 72 beats/min, and mental status had re-
turned to the baseline established prior to discontinuing
clonidine therapy. No further self-injurious behavior has
been reported during 6 months of continuing clonidine
therapy.
Discussion
This case illustrates the risk that self-injurious be-
havior may develop or be aggravated during cloni-
dine withdrawal. It also raises several questions of
potential theoretical and practical significance.
The attempts at self-suffocation, which were not
associated with dysphoric mood, intent to die, or
thought disorder, were evidently not suicide ges-
tures in the classic sense. They may have repre-
sented complex tics associated with Tourette’s
disorder or a phenomenon distinct from Tourette’s
disorder.
The present study used the patient as his own
control in a single-case A-B-A design. The appear-
ance of self-injurious behavior when clonidine was
discontinued, the rapid normalization of behavior
when clonidine was reinstated, and the parallel
changes in sympathetic tone, provide support for a
noradrenergic mechanism. It is of interest in this
connection that pain and asphyxia both are potent
stimuli of sympathetic discharge (Dillon JE, unpub-
lished data). Clonidine may have interrupted a posi-
tive feedback loop in which increased sympathetic
tone promoted behavior that in turn provoked sym-
pathetic discharge. Previous reports, implicating a
role for opiate systems in self-injurious behavior8 
8
and in the modulation of sympathetic activity in the
locus coeruleus,9 peripheral ganglia, and adrenals,lo
are consistent with the present data supporting a
possible noradrenergic mechanism in some forms of
self-injury.
In a study by Leckman et al5 of clonidine with-
drawal in Tourette’s disorder, patients were treated
with lower doses, up to 0.3 mg/day orally, over 12
weeks. These patients demonstrated increased mo-
tor activity, tics, blood pressure, pulse rate, urinary
catecholamines, and urinary and plasma 3-methoxy-
4-hydroxyphenylglycol. Motor restlessness, but not
tics, remitted dramatically on reinstitution of cloni-
dine. The 20-fJLg/kg/week dose of transdermal cloni-
dine used in the present case is apparently higher
than the 3- to 7.5-f..Lg/kg/day by mouth recom-
mended by Leckman et al,11 though it is compatible
with doses employed by others
This case illustrates the importance of close clin-
ical monitoring in patients being withdrawn from
clonidine following prolonged treatment at high
doses. It further suggests that in patients developing
tolerance to clonidine, a brief interlude of no treat-
ment or alternative treatment may permit reinstitu-
tion of clonidine at a lower dose.
Finally, the possibility is raised that adrenergic
dysregulation may play a mechanistic role in some
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patients with self-injurious behavior and that cloni-
dine might be useful in the treatment of self-injuri-
ous behavior unrelated to Tourette’s disorder.
Paradoxically, rodent studies suggest that clonidine
can induce automutilation. 13,14 While this provides
support for the hypothesis that adrenergic dysregu-
lation (perhaps especially associated with a2 presyn-
aptic receptors) might be linked with self-injurious
behavior, it recommends caution in the employment
of clonidine in clinical research trials. Further study
of the possible role of noradrenergic mechanisms in
self-injurious behavior is warranted.
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